Form 4: Artiva Biotherapeutics Executive Reports Stock Transactions
Statement of Changes in Beneficial Ownership
Artiva Biotherapeutics executive Gines Diego Miralles reports the acquisition of restricted stock units and stock options, detailing grant details and vesting schedules.
Summary
- Gines Diego Miralles, President & Head of R&D at Artiva Biotherapeutics, Inc., has reported transactions related to his beneficial ownership of the company's common stock.
- On May 18, 2026, Miralles was granted 77,500 restricted stock units (RSUs) under the Issuer's 2025 Inducement Plan, with no purchase price indicated.
- Additionally, on the same date, Miralles was granted a stock option award for 232,500 shares under the Issuer's 2025 Inducement Plan, with an exercise price of $9.22 per share.
- The stock option has an expiration date of May 17, 2036.
- Vesting for the stock option begins on May 15, 2027, with 25% of the shares becoming exercisable, and the remaining balance vesting monthly over the subsequent 36 months.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on standard executive compensation grants rather than significant financial performance or strategic shifts.
Positives
- Grant of restricted stock units and stock options to a key executive indicates continued incentive and alignment with company performance.
- The stock option grant at a price of $9.22 suggests a potential for future appreciation from the current market price.
- A structured vesting schedule for stock options encourages long-term commitment from the executive.
Negatives
- The filing does not provide information on the current market price of the stock at the time of the grant, making it difficult to assess the immediate value of the options.
- Details regarding the performance conditions, if any, for the RSUs are not specified.
Risks
- The value of the granted RSUs and stock options is subject to market fluctuations and the future performance of Artiva Biotherapeutics.
- The vesting schedule for the stock options means that a significant portion of the potential equity award is not immediately accessible.
Future Outlook
The vesting schedule for the stock options indicates a phased release of equity over several years, aligning executive incentives with long-term company growth.
Industry Context
StockSavvy.ai notes that the granting of stock options and RSUs to key executives is a common practice in the biotechnology sector to attract and retain talent, especially during early-stage development or growth phases. This aligns executive compensation with shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Gines Diego Miralles has granted a limited power of attorney to Fred Aslan, Jennifer Bush, and Andrew Cronauer to execute Forms 3, 4, and 5 on his behalf. | 05/18/2026 | Facilitates timely and accurate filing of Section 16 reports by designated individuals. |
Stakeholder Impact
- Shareholders: The grants align executive interests with long-term shareholder value, but the immediate impact on share price is minimal.
- Employees: The granting of awards under the 2025 Inducement Plan may set a precedent for other employee compensation structures.
- Management: Reinforces the compensation structure for key executives, potentially impacting retention.
Next Steps
- Vesting of restricted stock units and stock options according to the specified schedules.
- Potential future transactions by the reporting person based on vesting and market conditions.
Key Dates
| Date | Description |
|---|---|
| 05/18/2026 | Date of earliest transaction; grant date for RSUs and stock options. |
| 05/15/2027 | First vesting date for 25% of the stock option shares. |
| 05/17/2036 | Expiration date of the stock option. |
| 05/19/2026 | Date the Form 4 was signed. |
Keywords
Form 4, SEC Filing, Artiva Biotherapeutics, ARTV, Stock Options, Restricted Stock Units, Insider Trading, Executive Compensation, Beneficial Ownership, Inducement Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.